CAR T-cell therapy for relapsed or refractory multiple myeloma

Lancet Oncol. 2019 Jun;20(6):e297. doi: 10.1016/S1470-2045(19)30288-8. Epub 2019 May 10.

Author

Robert Stirrups

PMID: 31085047
DOI: 10.1016/S1470-2045(19)30288-8

No abstract available

Publication types

Comment

MeSH terms

B-Cell Maturation Antigen
Humans
Immunotherapy, Adoptive*
Multiple Myeloma*
T-Lymphocytes

Substances

B-Cell Maturation Antigen